S2 Table.The proliferation of PC9 cells after treatment with indicated concentrations of Gefitinib with or without the pre exposure of extrinsic N-Shh (0.5ug/ml) for 24 hours.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Method |  | Gefitinib | Total | *t/F*value | *P*value |
| 0nM | 20nM | 40nM | 80nM |
| G | 1.03±0.05 | 0.46±0.01 | 0.21±0.05 | 0.11±0.01 | 0.44±0.36 | 327.579 | <0.001 |
| S+G | 1.19±0.06 | 0.66±0.13 | 0.57±0.06 | 0.38±0.07 | 0.70±0.32 | 49.082 | <0.001 |
| Total | 1.09±0.11 | 0.56±0.14 | 0.39±0.20 | 0.24±0.15 | 0.57±0.36 | 189.336\* | <0.001\* |
| *t/F* value | -3.530 | -2.700 | -8.146 | -6.855 | 87.962\* | 2.215# | 0.126# |
| *P* value | 0.024 | 0.054 | 0.001 | 0.002 | <0.001\* |

G：Gifitinib；S：SHH；\*main effect；#interaction effect